Cellect Biotechnology ($APOP) shot up 14 percent in the current trading session as the company announced positive results from its clinical trial of ApoGraft™ in healthy donors. The primary objective for the study was to validate the Company's propriety method of stem cell selection by going through the process of production and characterization with ApoGraft™.
The study included 104 healthy donors of blood stem cells. Cellect’s technology enables the use of stem cells for regenerative therapies by eliminating mature cells while leaving the stem cells unharmed using a natural process occurring in the human body.
Dr. Yaron Pereg, Cellect’s Chief Development Officer, said, “These results from processing human stem cells for bone marrow transplantation using ApoGraft™ clearly demonstrated that Cellect’s proprietary platform could improve the outcome of stem cell transplantations in patients suffering from hematological malignancies.”
Cellect stock has gained 33 percent in the past 12 months while its Year to Date gain stands at over 115 percent. The stock is currently nearly 30 percent lower than its 52 weeks high of $8.78, offering an excellent opportunity for the investors to open a position with mid to long term horizon.